5-carboxyfluorescein diacetate has been researched along with bupropion in 2 studies
| Studies (5-carboxyfluorescein diacetate) | Trials (5-carboxyfluorescein diacetate) | Recent Studies (post-2010) (5-carboxyfluorescein diacetate) | Studies (bupropion) | Trials (bupropion) | Recent Studies (post-2010) (bupropion) |
|---|---|---|---|---|---|
| 41 | 0 | 13 | 3,392 | 755 | 1,329 |
| Protein | Taxonomy | 5-carboxyfluorescein diacetate (IC50) | bupropion (IC50) |
|---|---|---|---|
| Acetylcholine receptor subunit alpha | Homo sapiens (human) | 5.2693 | |
| Acetylcholine receptor subunit gamma | Homo sapiens (human) | 5.2693 | |
| Integrin alpha-5 | Homo sapiens (human) | 1.8 | |
| Acetylcholine receptor subunit beta | Homo sapiens (human) | 5.2693 | |
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | 0.9373 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.2003 | |
| Neuronal acetylcholine receptor subunit beta-4 | Homo sapiens (human) | 1.2028 | |
| Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens (human) | 1.367 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 1.9983 | |
| Neuronal acetylcholine receptor subunit alpha-7 | Homo sapiens (human) | 7.9 | |
| Neuronal acetylcholine receptor subunit alpha-4 | Homo sapiens (human) | 0.0135 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.0848 | |
| Acetylcholine receptor subunit delta | Homo sapiens (human) | 5.2693 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
2 other study(ies) available for 5-carboxyfluorescein diacetate and bupropion
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |